SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4724)7/3/1998 9:45:00 AM
From: Stewart Whitman  Read Replies (1) | Respond to of 6136
 
> but aren't there a lot of other expenses AGPH will incur as a
> result of these deals?

Yes, but perhaps there may not be quite as much of an increase in expenses as some might expect. They leverage the same sales force, manufacturing capability, and research staff. Also, it would seem that AGPH can sell the European marketing rights to products (AGPH purchased European rights for all three products).

Stew


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News